ASCO 2019 | PSMA ADC for prostate cancer

Daniel Petrylak

Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, discusses a phase 1 study of PSMA ADC, (antibody-drug conjugate) targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics